Vanguard Group Inc Allogene Therapeutics, Inc. Transaction History

Vanguard Group Inc

$6.44 Trillion
Q3 2025

A detailed history of Vanguard Group Inc transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 9,020,770 shares of ALLO stock, worth $11.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,020,770

Previous 8,259,128 9.22%

Holding current value

$11.1 Million

Previous $9.33 Million 19.86%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	BUY	$1.03 - $1.66 $784,491 - $1.26 Million	761,642 Added 9.22%	9,020,770 $11.2 Million
Q2 2025 Aug 11, 2025	BUY	$0.95 - $1.7 $181,996 - $325,677	191,575 Added 2.37%	8,259,128 $9.33 Million
Q1 2025 May 09, 2025	BUY	$1.4 - $2.84 $93,605 - $189,885	66,861 Added 0.84%	8,067,553 $11.8 Million
Q4 2024 Feb 11, 2025	SELL	$1.84 - $3.22 $601,692 - $1.05 Million	-327,007 Reduced 3.93%	8,000,692 $17 Million
Q3 2024 Nov 13, 2024	BUY	$2.08 - $3.5 $274,628 - $462,115	132,033 Added 1.61%	8,327,699 $23.3 Million
Q2 2024 Aug 13, 2024	SELL	$2.23 - $4.38 $26,532 - $52,113	-11,898 Reduced 0.14%	8,195,666 $19.1 Million
Q1 2024 May 10, 2024	SELL	$2.92 - $5.63 $2.4 Million - $4.63 Million	-823,261 Reduced 9.12%	8,207,564 $36.7 Million
Q4 2023 Feb 14, 2024	SELL	$2.28 - $3.5 $3.55 Million - $5.45 Million	-1,556,979 Reduced 14.71%	9,030,825 $29 Million
Q3 2023 Nov 14, 2023	BUY	$3.17 - $5.96 $9.78 Million - $18.4 Million	3,086,311 Added 41.14%	10,587,804 $33.6 Million
Q2 2023 Aug 14, 2023	BUY	$4.53 - $6.74 $888,591 - $1.32 Million	196,157 Added 2.69%	7,501,493 $37.3 Million
Q1 2023 May 15, 2023	BUY	$4.92 - $8.21 $197,365 - $329,344	40,115 Added 0.55%	7,305,336 $36.1 Million
Q4 2022 Feb 10, 2023	BUY	$5.62 - $11.11 $574,021 - $1.13 Million	102,139 Added 1.43%	7,265,221 $45.7 Million
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $12.8 Million - $21.5 Million	-1,243,065 Reduced 14.79%	7,163,082 $77.4 Million
Q2 2022 Aug 12, 2022	BUY	$6.78 - $12.28 $11.2 Million - $20.3 Million	1,652,167 Added 24.46%	8,406,147 $95.8 Million
Q1 2022 May 13, 2022	BUY	$7.65 - $15.29 $92,878 - $185,635	12,141 Added 0.18%	6,753,980 $61.5 Million
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $605,542 - $1.13 Million	46,119 Added 0.69%	6,741,839 $101 Million
Q3 2021 Nov 12, 2021	BUY	$21.01 - $27.64 $1.96 Million - $2.58 Million	93,414 Added 1.41%	6,695,720 $172 Million
Q2 2021 Aug 13, 2021	BUY	$23.49 - $35.8 $155 Million - $236 Million	6,602,306 New	6,602,306 $172 Million

Others Institutions Holding ALLO

# of Institutions

175

Shares Held

146M

Call Options Held

122K

Put Options Held

36.3K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $177M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Allogene Therapeutics, Inc. Transaction History